FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3101587283> ?p ?o ?g. }

• W3101587283 endingPage "A328" @default.
• W3101587283 startingPage "A328" @default.
• W3101587283 abstract "Background The phase 3 IMspire150 study ( NCT02908672 ) demonstrated improved progression-free survival (PFS) with first-line atezolizumab (A) vs placebo (P) combined with vemurafenib (V) + cobimetinib (C) in patients with BRAF V600 mutation–positive advanced melanoma (15.1 vs 10.6 months; hazard ratio [HR] 0.78; 95% confidence interval [CI] 0.63–0.97; P=0.0249). Objective response has been associated with increased survival with chemotherapy and targeted therapies, but it is unclear whether the association holds for immunotherapy. In this exploratory analysis, we evaluated the impact of response on survival outcomes in patients treated with A+V+C or P+V+C in the IMspire150 study. Methods 514 patients were randomized 1:1 to A+V+C (n=256) or P+V+C (n=258). Patients received V+C in cycle 1; A or P was added on days 1+15 from cycle 2 onward. The primary endpoints for this exploratory analysis were PFS and overall survival (OS), estimated using the Kaplan-Meier method. Outcomes were analyzed by investigator-assessed best overall response (BOR) per RECIST v1.1 (complete response [CR] vs partial response [PR] vs stable disease [SD]). Results Median follow-up was 18.9 mo. In the A+V+C arm, BOR was CR (n=41), PR (n=129), and SD (n=58); in the P+V+C arm, BOR was CR (n=46), PR (n=122), and SD (n=58). An imbalance in baseline prognostic factors (eg, lactate dehydrogenase, tumor burden measures) was noted across response categories in both treatment arms, with favorable factors more prevalent in patients with CR and unfavorable factors more prevalent in patients with PR/SD. Improvement in PFS and OS was observed with A+V+C vs P+V+C in patients with PR, with 2-year PFS rates of 42.1% vs 24.6% and 2-year OS rates of 69.1% vs 56.1% with A+V+C vs P+V+C (table 1). In patients with CR, median PFS and OS were not yet reached in either arm, with 2-year PFS rates of 64.6% vs 59.8% and 2-year OS rates of 82.6% vs 82.8% with A+V+C vs P+V+C. PFS and OS outcomes were poor in both treatment arms in patients with SD, with 2-year PFS rates of 10.7% vs not estimable (NE) and 2-year OS rates of 36.6% vs 29.3% with A+V+C vs P+V+C. Abstract 301 Table 1 PFS and OS outcomes with A+V+C vs P+V+C by BOR per RECIST v1.1 Conclusions PFS and OS improvement was observed for A+V+C vs P+V+C for patients who achieved PR. CR is associated with improved PFS and OS with both A+V+C and P+V+C. Further follow-up is required to determine the impact of A+C+V vs P+C+V on survival outcomes. Trial Registration ClinicalTrials. gov, NCT02908672" @default.
• W3101587283 created "2020-11-23" @default.
• W3101587283 creator A5008333301 @default.
• W3101587283 creator A5010628808 @default.
• W3101587283 creator A5012502212 @default.
• W3101587283 creator A5015081105 @default.
• W3101587283 creator A5027712976 @default.
• W3101587283 creator A5029398339 @default.
• W3101587283 creator A5046386901 @default.
• W3101587283 creator A5048111860 @default.
• W3101587283 creator A5056132643 @default.
• W3101587283 creator A5056227404 @default.
• W3101587283 creator A5063245135 @default.
• W3101587283 creator A5071263994 @default.
• W3101587283 creator A5081821803 @default.
• W3101587283 creator A5088416686 @default.
• W3101587283 creator A5089319059 @default.
• W3101587283 creator A5090633646 @default.
• W3101587283 creator A5091628280 @default.
• W3101587283 date "2020-11-01" @default.
• W3101587283 modified "2023-10-11" @default.
• W3101587283 title "301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study" @default.
• W3101587283 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0301" @default.
• W3101587283 hasPublicationYear "2020" @default.
• W3101587283 type Work @default.
• W3101587283 sameAs 3101587283 @default.
• W3101587283 citedByCount "0" @default.
• W3101587283 crossrefType "journal-article" @default.
• W3101587283 hasAuthorship W3101587283A5008333301 @default.
• W3101587283 hasAuthorship W3101587283A5010628808 @default.
• W3101587283 hasAuthorship W3101587283A5012502212 @default.
• W3101587283 hasAuthorship W3101587283A5015081105 @default.
• W3101587283 hasAuthorship W3101587283A5027712976 @default.
• W3101587283 hasAuthorship W3101587283A5029398339 @default.
• W3101587283 hasAuthorship W3101587283A5046386901 @default.
• W3101587283 hasAuthorship W3101587283A5048111860 @default.
• W3101587283 hasAuthorship W3101587283A5056132643 @default.
• W3101587283 hasAuthorship W3101587283A5056227404 @default.
• W3101587283 hasAuthorship W3101587283A5063245135 @default.
• W3101587283 hasAuthorship W3101587283A5071263994 @default.
• W3101587283 hasAuthorship W3101587283A5081821803 @default.
• W3101587283 hasAuthorship W3101587283A5088416686 @default.
• W3101587283 hasAuthorship W3101587283A5089319059 @default.
• W3101587283 hasAuthorship W3101587283A5090633646 @default.
• W3101587283 hasAuthorship W3101587283A5091628280 @default.
• W3101587283 hasBestOaLocation W31015872832 @default.
• W3101587283 hasConcept C121608353 @default.
• W3101587283 hasConcept C126322002 @default.
• W3101587283 hasConcept C142724271 @default.
• W3101587283 hasConcept C143998085 @default.
• W3101587283 hasConcept C204787440 @default.
• W3101587283 hasConcept C207103383 @default.
• W3101587283 hasConcept C27081682 @default.
• W3101587283 hasConcept C2775949291 @default.
• W3101587283 hasConcept C2776131300 @default.
• W3101587283 hasConcept C2777701055 @default.
• W3101587283 hasConcept C2780057760 @default.
• W3101587283 hasConcept C2780739268 @default.
• W3101587283 hasConcept C2994587330 @default.
• W3101587283 hasConcept C3019894029 @default.
• W3101587283 hasConcept C44249647 @default.
• W3101587283 hasConcept C71924100 @default.
• W3101587283 hasConcept C90924648 @default.
• W3101587283 hasConceptScore W3101587283C121608353 @default.
• W3101587283 hasConceptScore W3101587283C126322002 @default.
• W3101587283 hasConceptScore W3101587283C142724271 @default.
• W3101587283 hasConceptScore W3101587283C143998085 @default.
• W3101587283 hasConceptScore W3101587283C204787440 @default.
• W3101587283 hasConceptScore W3101587283C207103383 @default.
• W3101587283 hasConceptScore W3101587283C27081682 @default.
• W3101587283 hasConceptScore W3101587283C2775949291 @default.
• W3101587283 hasConceptScore W3101587283C2776131300 @default.
• W3101587283 hasConceptScore W3101587283C2777701055 @default.
• W3101587283 hasConceptScore W3101587283C2780057760 @default.
• W3101587283 hasConceptScore W3101587283C2780739268 @default.
• W3101587283 hasConceptScore W3101587283C2994587330 @default.
• W3101587283 hasConceptScore W3101587283C3019894029 @default.
• W3101587283 hasConceptScore W3101587283C44249647 @default.
• W3101587283 hasConceptScore W3101587283C71924100 @default.
• W3101587283 hasConceptScore W3101587283C90924648 @default.
• W3101587283 hasIssue "Suppl 3" @default.
• W3101587283 hasLocation W31015872831 @default.
• W3101587283 hasLocation W31015872832 @default.
• W3101587283 hasOpenAccess W3101587283 @default.
• W3101587283 hasPrimaryLocation W31015872831 @default.
• W3101587283 hasRelatedWork W1051628 @default.
• W3101587283 hasRelatedWork W12291014 @default.
• W3101587283 hasRelatedWork W13397619 @default.
• W3101587283 hasRelatedWork W13460688 @default.
• W3101587283 hasRelatedWork W2776280 @default.
• W3101587283 hasRelatedWork W3551421 @default.
• W3101587283 hasRelatedWork W4310718 @default.
• W3101587283 hasRelatedWork W5346711 @default.
• W3101587283 hasRelatedWork W7729919 @default.
• W3101587283 hasRelatedWork W12611928 @default.
• W3101587283 hasVolume "8" @default.
• W3101587283 isParatext "false" @default.
• W3101587283 isRetracted "false" @default.

• next